Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2024

  1. Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

    ESMO Open, Vol. 9, Núm. 10

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR